Sax Wealth Advisors LLC Purchases 1,532 Shares of Insulet Co. (NASDAQ:PODD)

Sax Wealth Advisors LLC grew its position in Insulet Co. (NASDAQ:PODD) by 101.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,044 shares of the medical instruments supplier’s stock after buying an additional 1,532 shares during the quarter. Sax Wealth Advisors LLC’s holdings in Insulet were worth $795,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Integrated Wealth Concepts LLC grew its stake in Insulet by 1.7% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock valued at $596,000 after purchasing an additional 42 shares during the last quarter. Glenmede Trust Co. NA lifted its holdings in shares of Insulet by 2.3% during the third quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock worth $484,000 after purchasing an additional 47 shares during the period. Graypoint LLC boosted its position in Insulet by 5.3% in the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock valued at $243,000 after buying an additional 47 shares during the last quarter. Wedmont Private Capital increased its holdings in Insulet by 3.5% in the 3rd quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier’s stock worth $326,000 after buying an additional 48 shares during the period. Finally, OVERSEA CHINESE BANKING Corp Ltd raised its position in Insulet by 4.7% during the 3rd quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 1,076 shares of the medical instruments supplier’s stock worth $250,000 after buying an additional 48 shares during the last quarter.

Insiders Place Their Bets

In other Insulet news, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This trade represents a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.47% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Citigroup increased their price objective on shares of Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Canaccord Genuity Group increased their price target on Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Barclays boosted their price objective on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Morgan Stanley raised their target price on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. Finally, Raymond James boosted their price target on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a report on Monday, October 14th. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $272.81.

Insulet Stock Performance

NASDAQ PODD opened at $275.81 on Friday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $279.77. The company has a market cap of $19.35 billion, a PE ratio of 47.23, a price-to-earnings-growth ratio of 3.41 and a beta of 1.22. The stock’s 50 day simple moving average is $266.30 and its 200-day simple moving average is $232.70.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.